Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + PD-1 inhibitor + gemcitabine/cisplatin first-line study in metastatic squamous non-small cell lung cancer
ChiCTR2000032815Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Sep 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar, gemcitabine and cisplatin in non-small cell lung cancer (NSCLC) and Pulmonary squamous cell carcinoma, sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Progression-free survival and Objective response rate. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
endostargemcitabinecisplatin
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2000032815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032815.